L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model

Bibliographic Details
Title: L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
Authors: Abrianna Beever, Nala Kachour, James Owens, Kayvan Sasaninia, Afsal Kolloli, Ranjeet Kumar, Santhamani Ramasamy, Christina Sisliyan, Wael Khamas, Selvakumar Subbian, Vishwanath Venketaraman
Source: Frontiers in Pharmacology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: diabetes, tuberculosis, host immune response, cytokine imbalance, redox imbalance, Therapeutics. Pharmacology, RM1-950
More Details: Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb infection and are more susceptible to reactivation of LTBI to active diseases. T2DM cases are known to have glutathione (GSH) deficiency and impaired immune cell function, including the granulomatous response to M. tb infection. We have previously reported that liposomal glutathione (L-GSH) supplementation can restore the immune cell effector responses of T2DM cases. However, the effects of L-GSH supplementation on the bactericidal activities of first-line anti-TB drug rifampicin (RIF) against M. tb infection have yet to be explored. The aim of this study is to elucidate the effects of L-GSH supplementation in conjunction with RIF treatment during an active M. tb infection in a diabetic mouse model. In this study, we evaluated total and reduced levels of GSH, cytokine profiles, malondialdehyde (MDA) levels, M. tb burden, and granulomatous response in the lungs. We show that L-GSH supplementation caused a significant reduction in M. tb burden in the lungs, decreased oxidative stress, and increased the production of IFN-γ, TNF-α, IL-17, IL-10, and TGF-β1compared to the untreated mice. In addition, L-GSH supplementation in conjunction with RIF treatment achieved better control of M. tb infection in the lungs and significantly reduced the levels of oxidative stress compared to treatment with RIF alone. Moreover, L-GSH in conjunction with RIF significantly increased TGF-β1 levels compared to treatment with RIF alone. These findings suggest potential therapeutic benefits of L-GSH supplementation in conjunction with first-line antibiotic therapy against M. tb infection in individuals with T2DM.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.879729/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2022.879729
Access URL: https://doaj.org/article/edb1b8e90015458cb66213afbf980ff0
Accession Number: edsdoj.b1b8e90015458cb66213afbf980ff0
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2022.879729
Published in:Frontiers in Pharmacology
Language:English